Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLD-2660 Tablet vs Capsule PK Study
NCT04001998Phase 1Withdrawn
- Sponsor
- Blade Therapeutics, Inc.
- Start
- Feb 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dazcapistat in fibrosis (2 arms), sponsored by Blade Therapeutics, Inc. Primary endpoints: Area under the drug concentration-time curve from time zero to the last measurable concentration up to 40 days, AUC from time 0 to infinity up to 40 days and 4 more. Planned start Feb 2021; status: withdrawn.
02
Drugs
dazcapistat
03
Conditions
fibrosis
Beyond the preview
Go deeper on NCT04001998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04001998.